Castle Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CSTL and other ETFs, options, and stocks.

About CSTL

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. 

CEO
Derek J. Maetzold
CEODerek J. Maetzold
Employees
761
Employees761
Headquarters
Friendswood, Texas
HeadquartersFriendswood, Texas
Founded
2007
Founded2007
Employees
761
Employees761

CSTL Key Statistics

Market cap
979.28M
Market cap979.28M
Price-Earnings ratio
-74.54
Price-Earnings ratio-74.54
Dividend yield
Dividend yield
Average volume
490.15K
Average volume490.15K
High today
$34.38
High today$34.38
Low today
$33.38
Low today$33.38
Open price
$33.95
Open price$33.95
Volume
320.59K
Volume320.59K
52 Week high
$35.49
52 Week high$35.49
52 Week low
$14.59
52 Week low$14.59

Stock Snapshot

The current Castle Biosciences(CSTL) stock price is $33.55, with a market capitalization of 979.28M. The stock trades at a price-to-earnings (P/E) ratio of -74.54.

On 2025-11-19, Castle Biosciences(CSTL) stock moved within a range of $33.38 to $34.38. With shares now at $33.55, the stock is trading +0.5% above its intraday low and -2.4% below the session's peak.

Trading volume for Castle Biosciences(CSTL) stock has reached 320.59K, versus its average volume of 490.15K.

The stock's 52-week range extends from a low of $14.59 to a high of $35.49.

The stock's 52-week range extends from a low of $14.59 to a high of $35.49.

CSTL News

TipRanks 5d
Castle Biosciences announces new data on DecisionDx-Melanoma test

Castle Biosciences (CSTL) announced new data demonstrating the clinical value of its DecisionDx-Melanoma test in improving sentinel lymph node biopsy decision m...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CSTL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.